A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

Trial Profile

A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza HA vaccine (Flubio)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo
  • Most Recent Events

    • 04 Nov 2015 New source identified and integrated; Japan Pharmaceutical Information Center - Clinical Trials Information record (JapicCTI142493)
    • 04 Nov 2015 New trial record
    • 28 Oct 2015 Primary endpoint has been met. (The difference between the seroconversion rates and the ratio of GMTs of HI antibody titer against three vaccine stains at Day 21), as per an article published in the Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top